Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders.
about
Pharmacological characterization of two novel and potent 5-HT4 receptor agonists, RS 67333 and RS 67506, in vitro and in vivoGastric emptying in myotonic dystrophyStereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juiceEvidence of impaired cisapride metabolism in neonatesEffects of cisapride on gall bladder emptying, intestinal transit, and serum deoxycholate: a prospective, randomised, double blind, placebo controlled trialInfluence of coadministration of fluoxetine on cisapride pharmacokinetics and QTc intervals in healthy volunteers.Retrospective analysis of cisapride-induced QT changes in end-stage renal disease patients.Principles of applied neurogastroenterology: physiology/motility-sensation.Review article: cardiac adverse effects of gastrointestinal prokinetics.Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans.Effects of dietary factors on levodopa pharmacokinetics.Drug-induced ventricular tachyarrhythmia in isolated rabbit hearts with atrioventricular block.The relation between symptom improvement and gastric emptying in the treatment of diabetic and idiopathic gastroparesis.Functional dyspepsia.Effects of cisapride on gastric emptying of oil and aqueous meal components, hunger, and fullness.Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states.Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactionsRandomised controlled trial of cisapride in feed intolerance in preterm infantsPopulation pharmacokinetics of enterally administered cisapride in young infants with gastro-oesophageal reflux disease.Impact of gastric emptying on the pharmacokinetics of ethanol as influenced by cisaprideEmerging drugs for gastro-oesophageal reflux disease.Randomized clinical trial: effect of the 5-HT4 receptor agonist revexepride on reflux parameters in patients with persistent reflux symptoms despite PPI treatment.Atypical antipsychotic drugs and the risk of sudden cardiac death.Cisapride provides symptomatic relief in functional dyspepsia associated with gastric myoelectrical abnormality.Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.The cardiovascular safety profile of renzapride, a novel treatment for irritable bowel syndrome.Cisapride for the treatment of chronic idiopathic constipation.Effect of lactulose and fiber-rich diets on bile in relation to gallstone disease: an update.Pharmacology of the gastric pro-kinetic drug ecabapide (DQ-2511).Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers.Effects of mosapride on esophageal functions and gastroesophageal reflux.Effects of cisapride on QTc interval in neonates.Possible interaction between cisapride and digoxin.Design and evaluation of a two-layer floating tablet for gastric retention using cisapride as a model drug.Relationship between gastric emptying and clinical and biochemical factors in chronic haemodialysis patients.Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects.Cisapride inhibits meal-stimulated gastric acid secretion and post-prandial gastric acidity in subjects with gastro-oesophageal reflux disease.Oral domperidone has no additional effect on chronic functional constipation in children: a randomized clinical trial.Age-related differences in the direct cardiac effects of cisapride: narrower safety range in the hearts of young rabbits.VB20B7, a novel 5-HT-ergic agent with gastrokinetic activity. I. Interaction with 5-HT3 and 5-HT4 receptors.
P2860
Q24679818-E5D8357C-5917-46C5-9968-72C39EE00C07Q28218740-DD12C7EC-3091-4DF2-88A9-51A169A0A397Q28362551-5EFC2EB2-B083-4975-8E37-15A8A40C0B13Q28362557-4456A2DC-713B-4063-BE55-25C15B219741Q28364173-A8EC99BE-3EBA-40FA-9ABE-E2137FD9EAC1Q32049802-85394236-9D1C-4308-A1C6-30B8D1353DFDQ33145870-46EEB881-5A3D-477A-8EB0-B4D55EF9EBB1Q33717384-62E13241-373E-482E-9C58-87F7FF133C32Q33792373-7A740807-9045-42E5-AC5A-F6B41F344B60Q33844909-024FC16F-55AD-41D2-91F3-F091E248C2EFQ34109657-7883FC59-F8C3-4291-9598-A62E912BCA00Q34134389-12B20390-C445-4B80-9A79-DB7C3C22353FQ34368630-E6E0E91E-B134-439A-8B65-911D8798930FQ34409166-4D6A581B-1E1A-47EB-9F5D-4F544AE010D5Q34409382-96CD2864-9BA2-4CC5-A0A4-937B35F6F407Q35041505-64C9567F-A840-439E-984C-96A7711A0177Q35042153-CBD3C2E9-7A00-46D0-AC16-ECFBDBF4BD7FQ35287419-5E3DEE6A-70EE-4D4B-8776-CA34979FF60FQ36053789-E6796005-B7EB-40F7-8562-4C83068ADFCEQ36053797-B7ACC28D-80B3-4A0F-B067-6FC96B617255Q36150665-8E2AC485-92B5-405D-A885-DEF3B11EFD42Q36377218-C4E6A319-365F-49B0-AD17-C56CB82D14BBQ37269776-F3B2F583-C511-4EC9-928C-646A2ACDDA14Q39427802-9F96FE40-5D9D-4DDF-A39D-519ABF769A95Q39784655-595DF66F-6D85-4F7E-AF10-4143038E50BCQ40045695-D26BDF65-FA65-4A9F-8226-560142705BF9Q40952963-D5C51199-9B22-4CDC-AD6B-DD41BC39C0A3Q41466129-34D353F6-DD1C-41A5-82E8-A63E30CEB384Q41702387-59FC0666-369B-476B-896E-E684E77EF1A0Q42048821-E9BA7FED-C509-48F0-9E29-6846829E831AQ42995641-8DA9AF12-CACE-4988-8864-B52DBF414ACEQ43098123-CD27025D-B7F9-4687-9207-47AE51137886Q43528530-A4471BAE-E08B-4A4B-9EF4-6643021B2377Q43669988-70148A1F-9D22-4452-BB94-42FFF31915C7Q43720147-985C409E-32FB-4CC7-93C9-AB6FE58ACFCFQ43782284-9EB3A821-2225-4728-8593-C0129F922CDBQ44148256-C9FF68CE-8C3D-49AF-ACF1-265796C9774BQ44315944-98C3351D-7F4D-46C5-9660-4CAB5EDAA0A2Q44321540-100F6625-AD1B-4C30-9B57-D06D2301E310Q46752714-DBDDB7E1-EDA2-4E8C-B1F1-980204E36F64
P2860
Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Cisapride. An updated review o ...... intestinal motility disorders.
@en
type
label
Cisapride. An updated review o ...... intestinal motility disorders.
@en
prefLabel
Cisapride. An updated review o ...... intestinal motility disorders.
@en
P1433
P1476
Cisapride. An updated review o ...... intestinal motility disorders.
@en
P2093
P304
P356
10.2165/00003495-199447010-00008
P577
1994-01-01T00:00:00Z
P6179
1029867516